Strategic Business Plan 2020-2024

This Strategic Business Plan (SBP) describes the strategic direction of the Medicines Evaluation Board (MEB) in the coming period from 2020 to 2024. We used the previous SBP to plot a course to connect with medical practice, for example by improving the provision of information. We now wish to continue along that course in line with our core values – scientific, vigilant and connected – with the aim to improve confidence in medicines.